The liquid based Pap test differs from the conventional method because of its improved fixation, decreased obscuring factors and standardization of cell transfer. The sampling is free from operator dependent variation since processing is controlled by laboratory.
The collecting device is either combination of ayre's spatula and endocervical brush or a broom with detachable head. After collection of sample the device is rinsed or detachable head is dropped into the vial containing preservative, ensuring 100% of collected sample to be sent to the laboratory for processing. In SurePath method sample is centrifuged while in ThinPrep method sample is filtered. Both methods result in a well-preserved approximate monolayer of cells with a background devoid of blood, mucus and inflammatory cells. The end result is better specimen adequacy and improved cell morphology which leads to
• Increased detection rate of both low grade, high grade squamous intraepithelial lesions and glandular lesionu 'v .
• Decreased rate of ASC-H and ASCUSw 'x
• Significantly fewer "Unsatisfactory smears" reducing unnecessary repeat testing.
Overall there is better concordance with the simultaneous histopathological examination indicating increased accuracyx . Moreover, LBC allows an opportunity to perform HPV DNA test with residual sample as a second line test without the need to recall the patient, which favorably influences the economy. The major change in the screening guideline is as follows-
• Cervical cancer screening should begin at age 21 years
• Both conventional cytology and liquid based cytology can be used in screening.
• Women between 21 to 29 years should be screened by cytology alone every 3 years.
• Women between 30 to 65 years should be screened by cytology and HPV DNA test called co-testing every 5 years.
• If HPV test is not available or is not used the same group of women can be screened by cytology alone every 3 years.
• Women who are more than 65 years with previous screening reports negative or who have undergone hysterectomy for benign conditions do not need any further screening.
• Women who are HPV vaccinated should follow the same screening guidelines as unvaccinated women.
Updates on HPV vaccination :
Update I: According to 'Immunization technical advisory committee of Centre for Disease Control and Prevention (CDC)' a 2-dose schedule is recommended if HPV Vaccine is initiated before 15 th birthday 10 (0,6-12 months). This will provide similar protective efficacy compared to a 3-dose schedule but will allow potential cost savings.
Thus the new HPV immunization schedule for females will be as follows -
• Girls aged between 9 -14 years are recommended a 2 dose schedule (0,6 -12 months).
• For a 2 dose schedule, the second dose should be received 6 to 12months after the first dose.
Updates in Cervical Cancer Prevention Farhat Hussain
• HPV vaccine as part of routine immunization is recommended for females at age 11 or 12, but can begin as early as age 9.
• Vaccination is also recommended for older girls and younger females between 15 to 26 years who will be given a 3-dose schedule (0,1-2, 6 months).
• Vaccination is recommended through age 26 for women with deficient immune systems like HIV infection.
Update II:
All boys between 11 and 12 years will receive HPV vaccination like girls according to new guidlines¹ 1 . The aim is to prevent HPV infection in males that can cause cancers of anus, penis and mouth/throat. This also prevents genital warts. Vaccinating males may also provide additional protection to females.
Update III:
In addition to Bivalent and Quadrivalent HPV vaccine, another HPV vaccine is approved by FDA in 10 December 2014 called HPV-9 or Gardosil -9. It is available in United States and can be used for routine vaccination. It gives protection against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 48. In addition to prevent genital warts it gives protection against cervical cancer, vaginal and vulval cancer in females, anal and throat cancer in males and females and penile cancers in male.
Because it gives protection against 5 additional HPV types (when compared with quadrivalent vaccine) it gives additional 10% protection against HPV linked cancers including 15% of cervical cancer.
